Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 9/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 7/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 7/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509091 | 1.00 | ITGAL (0.49) | ITGALITGB2ICAM1CAPN1NPC1 | |
| SCHEMBL6509111 | 1.00 | ITGAL (0.49) | ITGALITGB2ICAM1CAPN1NPC1 | |
| SCHEMBL6497948 | 0.93 | ITGAL (0.49) | ITGALITGB2ICAM1CAPN1NPC1 | |
| SCHEMBL6497963 | 0.93 | ITGAL (0.49) | ITGALITGB2ICAM1CAPN1NPC1 | |
| SCHEMBL6497937 | 0.93 | ITGAL (0.49) | ITGALITGB2ICAM1CAPN1NPC1 | |
| SCHEMBL6497168 | 0.91 | ITGAL (0.48) | ITGALITGB2ICAM1CAPN1NPC1 | |
| SCHEMBL6497150 | 0.91 | ITGAL (0.48) | ITGALITGB2ICAM1CAPN1NPC1 | |
| SCHEMBL6497139 | 0.91 | ITGAL (0.48) | ITGALITGB2ICAM1CAPN1NPC1 | |
| SCHEMBL6498043 | 0.90 | ITGAL (0.47) | ITGALITGB2ICAM1CAPN1NPC1 | |
| SCHEMBL6498020 | 0.90 | ITGAL (0.47) | ITGALITGB2ICAM1CAPN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-20190218194-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-07-18 | — | — | US | disclosed |
| EP-3363434-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-2970131-B1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170088529-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9365527-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160031839-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970131-A2 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20140315961-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2014153100-A2 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-6960595-B2 | 5-6 to 5-7 Heterobicycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20030018023-A1 | 5-6 or 5-7 Heterobicycles as Factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-23 | — | — | US | disclosed |
| US-5552554-A | Imidazole and triazole carboxylates, and processes for preparing 2,4-oxazolidinediones | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018023-A1 | 5-6 or 5-7 Heterobicycles as Factor Xa inhibitors | HABP2, SERPINC1, F7 | ITGAL 1467/4885ITGB2 2406/4885ICAM1 3283/4885 |
| US-20140315961-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ITGAL 4314/4885ITGB2 4410/4885ICAM1 3121/4885 |
| US-20160031839-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ITGAL 4314/4885ITGB2 4410/4885ICAM1 3121/4885 |
| US-20190218194-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ITGAL 4314/4885ITGB2 4410/4885ICAM1 3121/4885 |
| US-20170088529-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | ITGAL 4314/4885ITGB2 4410/4885ICAM1 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.